Chronic Lymphocytic Leukemia | Specialty

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

October 16th 2019

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Dr. Mato on Utilizing CAR T Cells in CLL

October 15th 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

Novel Agents, Combos Transforming Treatment in MCL and CLL

October 14th 2019

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

October 8th 2019

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm

October 7th 2019

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Dr. Eradat Discusses Data With Acalabrutinib in CLL

October 5th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Smith on Utilizing Lenalidomide in CLL

October 4th 2019

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

October 4th 2019

James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of venetoclax and obinutuzumab versus chlorambucil and obinutuzumab as frontline therapy in chronic lymphocytic leukemia.

Dr. Eradat on the CAPTIVATE Trial in CLL

September 24th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unprecedented aspects of the phase II CAPTIVATE trial in chronic lymphocytic leukemia (CLL).

Dr. Smith on Ibrutinib-Based Therapies in CLL

September 23rd 2019

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.

Dr. Eradat on the Unmet Needs in CLL

September 19th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.

Breakthrough Therapies Enrich Evolving CLL Paradigm

September 19th 2019

Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.

Secondary Cancer Risk Remains an Unresolved Issue in CLL

September 18th 2019

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

Novel Combos Are Shaking Up the CLL Landscape

September 15th 2019

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

Future of PI3K Inhibition in FL and CLL

September 13th 2019

PI3K Inhibitors in Management of R/R Follicular Lymphoma

September 13th 2019

PI3K Inhibitors in Management of CLL

September 13th 2019

Common Toxicities With PI3K Inhibition

September 13th 2019